Drug intelligence / Profile preview

Ad-Tie2

Development stage: Preclinical
Lead developer: AnGes
Modality: Adenoviral Vectors → Other Viral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Intratumoral

Overview

Ad-Tie2 is an adenoviral vector gene therapy designed to deliver and express a soluble form of the endothelium-specific tyrosine kinase receptor Tie2. This therapeutic approach aims to exert anti-angiogenic and antitumor effects by interfering with the normal signaling pathways of the Tie2 receptor, which is crucial for blood vessel formation and tumor growth. It has been investigated in preclinical models for its potential in treating metastatic renal cell carcinoma.

Targets

TEK (Tie2)ANGPT1 (Angiopoietin-1)ANGPT2 (Angiopoietin-2)

Beyond the preview

Go deeper on Ad-Tie2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ad-Tie2.

Explore the full profile